Open access
Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.
Mathieu Meunier
S. Thepot
Stanislas Nimubona
Mélanie Véloso
Thibaud Lefèbvre
Z. Karim
M. Ropert-Bouchet
Frédéric Garban
S. Amé
Claire Reynes
C. Salanoubat
Vincent Parinet
K. Laribi
P. Eftekhari
Jacques Delaunay
G. Venton
Clémence Santana
S. Chéze
S. Dimicoli-Salazar
A. Toma
Mathieu Molimard
P. Fenaux
Valérie Rolland-Neyret
Sandra David-Tchouda
S. Park
Medicine
Abstract
Not available.